No Need to Stop Estrogen in Transgender Women Before Gender-Affirming Surgery No Need to Stop Estrogen in Transgender Women Before Gender-Affirming Surgery
Transgender women can safely maintain their estrogen hormone therapy during gender-affirming surgery without an increased risk of venous thromboembolism (VTE), according to a new study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 20, 2021 Category: Surgery Tags: Diabetes & Endocrinology News Source Type: news

Estrogen Therapy Need Not Stop for Gender - Affirming Surgery
Authors find that perioperative venous thromboembolism rarely occurs, regardless of suspension of hormone therapy prior to surgery (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 19, 2021 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Surgery, Journal, Source Type: news

Estrogen Therapy Need Not Stop for Gender-Affirming Surgery
TUESDAY, Jan. 19, 2021 -- For transgender and gender nonbinary (TGNB) patients undergoing primary vaginoplasty, perioperative venous thromboembolism (VTE) occurs rarely, regardless of whether hormone therapy is suspended prior to surgery, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 19, 2021 Category: Pharmaceuticals Source Type: news

Score Aids Treatment Decision in Mild Large-Vessel Stroke Score Aids Treatment Decision in Mild Large-Vessel Stroke
Location and length of thrombus can identify those at highest risk for early neurologic deterioration, flagging those who may be the best candidates for thrombectomy.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 15, 2021 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

Be Part of the Solution: Vax Up!
JEMS proudly gives two thumbs up to the Ohio Department of Public Safety, Division of EMS, which, in partnership with the Mentor Fire Department, created an outstanding “Vax Up” edition of their “Be Part of the Solution” public service announcement (PSA) series. The Division of EMS created, and is encouraging distribution, of this PSA as a resource to encourage EMS providers to receive the COVID-19 vaccine, to highlight the importance of vaccination to all public safety personnel and to the community, and to encourage the populations in the upcoming phases of the vaccination plan to be immunized ...
Source: JEMS Patient Care - January 14, 2021 Category: Emergency Medicine Authors: A.J. Heightman, MPA, EMT-P Tags: Commentary Coronavirus Spotlight EMS EMT Medicine Paramedic Source Type: news

Be Part of the Solution: Vax Up!
JEMS proudly gives two thumbs up to the Ohio Department of Public Safety, Division of EMS, which, in partnership with the Mentor Fire Department, created an outstanding “Vax Up” edition of their “Be Part of the Solution” public service announcement (PSA) series. The Division of EMS created, and is encouraging distribution, of this PSA as a resource to encourage EMS providers to receive the COVID-19 vaccine, to highlight the importance of vaccination to all public safety personnel and to the community, and to encourage the populations in the upcoming phases of the vaccination plan to be immunized ...
Source: JEMS Administration and Leadership - January 14, 2021 Category: Emergency Medicine Authors: A.J. Heightman, MPA, EMT-P Tags: Commentary Coronavirus Spotlight EMS EMT Medicine Paramedic Source Type: news

Be Part of the Solution: Vax Up!
JEMS proudly gives two thumbs up to the Ohio Department of Public Safety, Division of EMS, which, in partnership with the Mentor Fire Department, created an outstanding “Vax Up” edition of their “Be Part of the Solution” public service announcement (PSA) series. The Division of EMS created, and is encouraging distribution, of this PSA as a resource to encourage EMS providers to receive the COVID-19 vaccine, to highlight the importance of vaccination to all public safety personnel and to the community, and to encourage the populations in the upcoming phases of the vaccination plan to be immunized ...
Source: JEMS Latest News - January 14, 2021 Category: Emergency Medicine Authors: A.J. Heightman, MPA, EMT-P Tags: Commentary Coronavirus Spotlight EMS EMT Medicine Paramedic Source Type: news

Be Part of the Solution: Vax Up!
JEMS proudly gives two thumbs up to the Ohio Department of Public Safety, Division of EMS, which, in partnership with the Mentor Fire Department, created an outstanding “Vax Up” edition of their “Be Part of the Solution” public service announcement (PSA) series. The Division of EMS created, and is encouraging distribution, of this PSA as a resource to encourage EMS providers to receive the COVID-19 vaccine, to highlight the importance of vaccination to all public safety personnel and to the community, and to encourage the populations in the upcoming phases of the vaccination plan to be immunized ...
Source: JEMS: Journal of Emergency Medical Services News - January 14, 2021 Category: Emergency Medicine Authors: A.J. Heightman, MPA, EMT-P Tags: Commentary Coronavirus Spotlight EMS EMT Medicine Paramedic Source Type: news

Be Part of the Solution: Vax Up!
JEMS proudly gives two thumbs up to the Ohio Department of Public Safety, Division of EMS, which, in partnership with the Mentor Fire Department, created an outstanding “Vax Up” edition of their “Be Part of the Solution” public service announcement (PSA) series. The Division of EMS created, and is encouraging distribution, of this PSA as a resource to encourage EMS providers to receive the COVID-19 vaccine, to highlight the importance of vaccination to all public safety personnel and to the community, and to encourage the populations in the upcoming phases of the vaccination plan to be immunized ...
Source: JEMS Operations - January 14, 2021 Category: Emergency Medicine Authors: A.J. Heightman, MPA, EMT-P Tags: Commentary Coronavirus Spotlight EMS EMT Medicine Paramedic Source Type: news

Be Part of the Solution: Vax Up!
JEMS proudly gives two thumbs up to the Ohio Department of Public Safety, Division of EMS, which, in partnership with the Mentor Fire Department, created an outstanding “Vax Up” edition of their “Be Part of the Solution” public service announcement (PSA) series. The Division of EMS created, and is encouraging distribution, of this PSA as a resource to encourage EMS providers to receive the COVID-19 vaccine, to highlight the importance of vaccination to all public safety personnel and to the community, and to encourage the populations in the upcoming phases of the vaccination plan to be immunized ...
Source: JEMS Special Topics - January 14, 2021 Category: Emergency Medicine Authors: A.J. Heightman, MPA, EMT-P Tags: Commentary Coronavirus Spotlight EMS EMT Medicine Paramedic Source Type: news

Bilateral Pulmonary Embolism While Receiving Tranexamic Acid Bilateral Pulmonary Embolism While Receiving Tranexamic Acid
This case of bilateral pulmonary embolism in a healthy, active middle-aged woman reinforces the possible increased risk of thromboembolism in patients receiving tranexamic acid.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 13, 2021 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Hydroxychloroquine Level Tied to Thrombosis Risk in Lupus
Rate of thrombotic events lower for patients with mean HCQ blood levels>1,068 versus
Source: The Doctors Lounge - Oncology - January 11, 2021 Category: Cancer & Oncology Tags: Family Medicine, Internal Medicine, Oncology, Pathology, Pharmacy, Rheumatology, Journal, Source Type: news

Hydroxychloroquine Level Tied to Thrombosis Risk in Lupus
MONDAY, Jan. 11, 2021 -- For patients with systemic lupus erythematosus (SLE), lower hydroxychloroquine (HCQ) blood levels are associated with a higher risk for thrombotic events, according to a study published online Jan. 5 in Arthritis&... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 11, 2021 Category: Pharmaceuticals Source Type: news

COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms, Thorax
Review explores the pathobiological mechanisms of immunothrombosis and VTE in COVID-19 focusing on COVID-19-associated coagulopathy, pathology, endothelial dysfunction and haemostasis, the immune system and thrombosis, genetic associations and additional thrombotic mechanisms. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 8, 2021 Category: Consumer Health News Source Type: news

High HCQ Blood Level May Lower Thrombosis Risk in Lupus High HCQ Blood Level May Lower Thrombosis Risk in Lupus
Studies suggest that it may protect against thrombosis, but the optimal dosing for this purpose remains unknown, wrote Michelle Petri, MD, of Johns Hopkins University, Baltimore, and colleagues.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - January 7, 2021 Category: Rheumatology Tags: Rheumatology News Source Type: news

NETs a Possible Therapeutic Target for COVID-19 Thrombosis? NETs a Possible Therapeutic Target for COVID-19 Thrombosis?
Neutrophil extracellular traps, weblike DNA and protein strands now known to contribute to thrombosis, are more frequent and are denser in COVID-19 STEMI patients, suggesting a potential target for therapy.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 31, 2020 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

Assessment of neutrophil extracellular traps in coronary thrombus of case series of patients with COVID-19
(JAMA Network) Severe COVID-19 is characterized by the intense formation of neutrophil extracellular traps (NETs), leading to the blockage of microvessels, as shown in pulmonary samples. The occurrence of ST-elevated myocardial infarction (STEMI) is a serious cardiac manifestation of COVID-19; the intrinsic mechanism of coronary thrombosis appears to still be unknown. This case series report of five patients sought to   determine the role of NETs in coronary thrombosis in patients with COVID-19. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 29, 2020 Category: Infectious Diseases Source Type: news

Venous Thromboembolism and COVID-19 Venous Thromboembolism and COVID-19
This case adds to the emerging evidence for venous thromboembolism as a complication of COVID-19.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 16, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

RedHill's P2/3 COVID-19 candidate Opaganib reduces ARDS-related blood clotting
(RedHill Biopharma) RedHill Biopharma (Nasdaq: RDHL) today announced promising preliminary results from a preclinical study with opaganib, a novel, orally administered sphingosine kinase 2 (SK2) selective inhibitor, administered at 250mg/kg, demonstrating a reduction of thrombosis (blood clotting) in an acute respiratory distress syndrome (ARDS) - a preclinical animal model designed to measure thrombotic risks. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 15, 2020 Category: International Medicine & Public Health Source Type: news

New follow-up phase III data reinforce the long-term benefit of Roche ’s Hemlibra for people with haemophilia A
Basel, 7 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from a new analysis of pooled, three-year follow-up data of 401 people with haemophilia A from the pivotal HAVEN 1-4 studies, which reinforce the long-term efficacy and safety profile of Hemlibra ® (emicizumab).[1]These data, from adults, adolescents and children with haemophilia A with and without factor VIII inhibitors, were presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 5-8 December 2020.“The long-term benefit of Hemlibra, with a consistent safety profile and durably effect...
Source: Roche Media News - December 7, 2020 Category: Pharmaceuticals Source Type: news

New follow-up phase III data reinforce the long-term benefit of Roche ’s Hemlibra for people with haemophilia A
Basel, 7 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from a new analysis of pooled, three-year follow-up data of 401 people with haemophilia A from the pivotal HAVEN 1-4 studies, which reinforce the long-term efficacy and safety profile of Hemlibra ® (emicizumab).[1]These data, from adults, adolescents and children with haemophilia A with and without factor VIII inhibitors, were presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 5-8 December 2020.“The long-term benefit of Hemlibra, with a consistent safety profile and durably effect...
Source: Roche Investor Update - December 7, 2020 Category: Pharmaceuticals Source Type: news

Delayed presentation of blunt inferior vena cava injury following high-speed motor vehicle collision - Tupper H, Reiter S, Rog CJ, French B, Hayes PG.
This is a report of a case of acute-on-chronic inferior vena cava thrombosis 10 years following blunt abdominal trauma from a motor vehicle collision. Although more common risk factors for this pathology include anatomical variation or the long-standing pr... (Source: SafetyLit)
Source: SafetyLit - December 5, 2020 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

What to Do When Anticoagulation Fails Patients With Cancer What to Do When Anticoagulation Fails Patients With Cancer
When a patient with cancer develops venous thromboembolism despite anticoagulation, how to help them comes down to clinical judgment, according to hematologist Neil Zakai, MD.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 2, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Review: Thromboembolism Risk High in COVID-19 Patients
TUESDAY, Dec. 1, 2020 -- The rate of thromboembolism is high in patients with COVID-19 and is associated with increased odds of mortality, according to a review published online Nov. 20 in EClinicalMedicine. Mahmoud B. Malas, M.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 1, 2020 Category: Pharmaceuticals Source Type: news

COVID-19 and Risk of Clotting:'Be Proactive About Prevention'COVID-19 and Risk of Clotting:'Be Proactive About Prevention '
How best to manage the increased risk of arterial and venous thrombosis in COVID-19 patients is the subject of a new review article.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 1, 2020 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

NICE rapid guideline for COVID-19: reducing the risk of venous thromboembolism
NICE has published guidance on pharmacological VTE prophylaxis for patients being treated for COVID-19 pneumonia in hospital or a community setting, such as a ‘hospital at home’ service or COVID-19 ‘virtual ward’.  (Source: NHS Networks)
Source: NHS Networks - November 27, 2020 Category: UK Health Source Type: news

Ultrasound tracks DVT in patients with severe COVID-19
Ultrasound was used to track deep vein thrombosis (DVT) prevalence in patients...Read more on AuntMinnie.comRelated Reading: Ultrasound steps up in COVID-19 pandemic What causes PTE in COVID-19 patients? CTA still most common modality for PE diagnosis Use CTA to evaluate obese COVID-19 patients for PE risk Which ultrasound method is best for DVT? All of them (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 25, 2020 Category: Radiology Source Type: news

High-Dose Anticoagulation May Not Aid COVID-19 Patients
FRIDAY, Nov. 20, 2020 -- Higher doses of blood thinners are potentially harmful and have no clear benefits for hospitalized COVID-19 patients, according to a study published online Nov. 5 in Thrombosis Research. Lei Lynn, M.D., from George... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 20, 2020 Category: Pharmaceuticals Source Type: news

Rates of VTE, Major Bleeding High in Primary CNS Lymphoma
FRIDAY, Nov. 20, 2020 -- For patients with primary central nervous system lymphoma (PCNSL), the incidence of venous thromboembolism (VTE) and major bleeding is high, according to a study published in the November issue of Leukemia&... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 20, 2020 Category: Pharmaceuticals Source Type: news

COVID-19 rapid guideline: reducing the risk of venous thromboembolism in over 16s with COVID-19 [NG186], NICE (published 20th November 2020)
This guideline covers pharmacological VTE prophylaxis for patients being treated for COVID-19 pneumonia. It includes patients receiving treatment in hospital or in a community setting such as a'hospital at home'service or COVID-19'virtual ward'. The guideline applies to all patients with COVID-19 pneumonia, including those who have other conditions. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 20, 2020 Category: Consumer Health News Source Type: news

In-stent thrombosis after antiplatelet therapy conversion while awaiting coronary bypass
(Compuscript Ltd) In a new publication from Cardiovascular Innovations and Applications; DOI https://doi.org/10.15212/CVIA.2019.0589, Nathan Burke, Tawanna Charlton, Hussam Hawamdeh, and Ki Park from the University of Florida College of Medicine, Gainesville, Florida, USA consider a case study of in-stent thrombosis after antiplatelet therapy conversion while awaiting coronary bypass. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 19, 2020 Category: International Medicine & Public Health Source Type: news

VTEs Tied to Immune Checkpoint Inhibitor Cancer Treatment VTEs Tied to Immune Checkpoint Inhibitor Cancer Treatment
Cancer patients who receive an immune checkpoint inhibitor have more than a doubled rate of venous thromboembolism (VTE) during the subsequent 2 years according to an analysis of more than 2,800 patients.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 18, 2020 Category: Intensive Care Tags: Hematology-Oncology News Source Type: news

Genetics Tied to Thromboembolism Risk With Inflammatory Bowel Disease
WEDNESDAY, Nov. 18, 2020 -- Genetic variants in some patients with inflammatory bowel disease (IBD) are associated with a significantly increased risk for developing thromboembolic disease (TED), according to a study published online Oct. 21 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 18, 2020 Category: Pharmaceuticals Source Type: news

VTEs Tied to Immune Checkpoint Inhibitor Cancer Treatment VTEs Tied to Immune Checkpoint Inhibitor Cancer Treatment
Patients with cancer who receive an immune checkpoint inhibitor have more than a doubled rate of venous thromboembolism during the subsequent 2 years, according to a large retrospective analysis.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 17, 2020 Category: Cancer & Oncology Tags: Cardiology News Source Type: news

AJR: Positive studies may get published faster
Radiology studies with positive conclusions, but not positive titles, are published...Read more on AuntMinnie.comRelated Reading: Synthetic DBT images could replace digital mammo COVID-19 patients more likely to have thromboembolism Remote reading is more complicated than flipping a switch Electronic consults may avoid unnecessary imaging COVID-19 associated with large vessel strokes (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 16, 2020 Category: Radiology Source Type: news

13.11.20: Not intended for U.S. and UK Media
Positive CHMP opinion for extension of rivaroxaban marketing authorization to treat venous thromboembolism (VTE) in childrenPediatric patients currently have limited therapeutic options and until now, there have been no approved oral treatments because of the absence of appropriate clinical trials / After approval, rivaroxaban would be the only oral Factor Xa Inhibitor authorized to treat VTE and prevent VTE recurrence in children / An oral suspension of rivaroxaban that does not require injections or regular monitoring has been developed to facilitate pediatric administration / CHMP opinion is based on the largest pediatr...
Source: Bayer IR Newsfeed: Events - November 13, 2020 Category: Pharmaceuticals Source Type: news

Moderate-to-Severe CKD Tied to Worse VTE Outcomes Moderate-to-Severe CKD Tied to Worse VTE Outcomes
A registry study of patients with venous thromboembolism (VTE) suggests moderate-to-severe chronic kidney disease (CKD) is associated with greater risks of death, VTE recurrence and major bleeding compared to mild or no CKD.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 10, 2020 Category: Intensive Care Tags: Cardiology News Source Type: news

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need f...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutane...
Source: Johnson and Johnson - November 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Scientists Have Uncovered the Likely Cause of a Serious COVID-19 Symptom: Blood Clotting
One of the more surprising symptoms of COVID-19 has been the blood clots that many patients, including younger ones, have experienced with the infection. The clots have in some cases led to dangerous blockages in the lungs, caused strokes and even death, even in people without a history of circulatory conditions. In a paper published in Science earlier this week, researchers provide a glimpse into what may be driving the clots triggered by COVID-19 infection. The group found that a specific set of antibodies known as autoantibodies—which are rogue versions of cells meant to defend the body from pathogens, but instead...
Source: TIME: Health - November 5, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

New Target to Combat COVID-Related Thrombosis? New Target to Combat COVID-Related Thrombosis?
More than half of patients hospitalized with COVID-19 have prothrombotic antiphospholipid autoantibodies in their blood, which may trigger to blood clots, new research suggests.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 4, 2020 Category: Intensive Care Tags: Cardiology News Source Type: news

The Specter of Endothelial Injury in COVID-19
Studies signal that damage to the endothelium--cells that cover blood vessels like wallpaper--could underpin the thrombosis and inflammation induced by coronavirus infection. (Source: The Scientist)
Source: The Scientist - November 3, 2020 Category: Science Tags: News & Opinion Source Type: news

COVID-19: Thromboembolic Events High Despite Prophylaxis COVID-19: Thromboembolic Events High Despite Prophylaxis
However, new US data show the rates of thromboembolism are not as high as reported in earlier studies from Asia and appear similar to what would be expected in other very sick patients in ICU.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 26, 2020 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revasculariz...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

DVT Screening, Early Treatment, Prevent PE in Necrotizing Pancreatitis DVT Screening, Early Treatment, Prevent PE in Necrotizing Pancreatitis
Ultrasound screening enabled identification and early treatment of extremity deep vein thrombosis (DVT), thereby preventing symptomatic pulmonary embolism (PE) in a single center trial.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - October 23, 2020 Category: Gastroenterology Tags: General Surgery News Source Type: news

Negative D-Dimer Can Safely Rule Out DVT as Standalone Test
FRIDAY, Oct. 16, 2020 -- Initial standalone D-dimer testing followed by whole-leg compression ultrasonography (CUS) in patients with positive D-dimer can safely rule out deep vein thrombosis (DVT), according to a study published online Oct. 15 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 16, 2020 Category: Pharmaceuticals Source Type: news

Leaflet Immobility and Thrombosis in TAVR Leaflet Immobility and Thrombosis in TAVR
How common is subclinical transcatheter heart valve thrombosis following TAVR? What are the potential clinical implications, and how should these patients be managed?European Heart Journal (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - October 14, 2020 Category: Radiology Tags: Cardiology Journal Article Source Type: news

Massive brainstem and cerebellum infarction due to traumatic extracranial vertebral artery dissection in a motor traffic accident: an autopsy case report - Wang T, Zhang J, Zou D, Chen Y.
Traumatic unilateral vertebral artery (VA) injury can cause focal thrombosis and may block the basilar artery which can further lead to ischemic stroke and massive cerebral infarction and subarachnoid hemorrhage and even rapid death. Here, we present an au... (Source: SafetyLit)
Source: SafetyLit - October 14, 2020 Category: International Medicine & Public Health Tags: Pedestrians and Bicycles Source Type: news

AHA News: How Much Do You Know About Thrombosis? Probably Not Enough
Title: AHA News: How Much Do You Know About Thrombosis? Probably Not EnoughCategory: Health NewsCreated: 10/13/2020 12:00:00 AMLast Editorial Review: 10/14/2020 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - October 14, 2020 Category: Cardiology Source Type: news